Literature DB >> 3758158

The stress of a novel environment reduces formalin pain: possible role of serotonin.

F V Abbott, K B Franklin, B Connell.   

Abstract

Compared to rats that were given three daily sessions of habituation to a laboratory environment, non-habituated rats were behaviourally less reactive when pain was produced by 0.05 ml of 2.5% formalin injected s.c. in one hindpaw. This behavioural analgesia was equivalent to that produced by approximately 2.0 mg/kg morphine and was interpreted as analgesia induced by the stress of exposure to a novel environment. Methysergide (10 mg/kg) or 1-valine (200 mg/kg) alone, or combined with naloxone (0.1 or 2.0 mg/kg), reversed the effect of exposure to a novel environment. Naloxone itself had no significant effect. In habituated rats 1-valine reduced the response to formalin-induced pain whereas methysergide combined with naloxone increased it. It is concluded that analgesia induced by the stress of exposure to a novel environment depends on serotonin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3758158     DOI: 10.1016/0014-2999(86)90750-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Laboratory environmental factors and pain behavior: the relevance of unknown unknowns to reproducibility and translation.

Authors:  Jeffrey S Mogil
Journal:  Lab Anim (NY)       Date:  2017-03-22       Impact factor: 12.625

Review 2.  Factors affecting the reliability of behavioral assessments for rodent osteoarthritis models.

Authors:  Brittany Y Jacobs; Kyle D Allen
Journal:  Lab Anim       Date:  2019-08-20       Impact factor: 2.471

3.  Clonidine and yohimbine modulate the effects of naloxone on novelty-induced hypoalgesia.

Authors:  J Rochford; P Dawes
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  A thermal threshold assay to measure the nociceptive response to morphine sulphate in cattle.

Authors:  L C Machado Filho; J F Hurnik; K K Ewing
Journal:  Can J Vet Res       Date:  1998-07       Impact factor: 1.310

5.  Supraspinal Gbetagamma-dependent stimulation of PLCbeta originating from G inhibitory protein-mu opioid receptor-coupling is necessary for morphine induced acute hyperalgesia.

Authors:  Enrica Bianchi; Monica Norcini; Alan Smrcka; Carla Ghelardini
Journal:  J Neurochem       Date:  2009-07-27       Impact factor: 5.372

6.  Mesolimbic neuropeptide W coordinates stress responses under novel environments.

Authors:  Toshiyuki Motoike; Jeffrey M Long; Hirokazu Tanaka; Christopher M Sinton; Amber Skach; S Clay Williams; Robert E Hammer; Takeshi Sakurai; Masashi Yanagisawa
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-02       Impact factor: 11.205

7.  Pain in Times of Stress.

Authors:  Asma Hayati Ahmad; Rahimah Zakaria
Journal:  Malays J Med Sci       Date:  2015-12

8.  Effects of midazolam and naloxone in rats tested for sensitivity/reactivity to formalin pain in a familiar, novel or aversively conditioned environment.

Authors:  J A Harris; R F Westbrook
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

9.  Pain sensitivity and vasopressin analgesia are mediated by a gene-sex-environment interaction.

Authors:  Jeffrey S Mogil; Robert E Sorge; Michael L LaCroix-Fralish; Shad B Smith; Anny Fortin; Susana G Sotocinal; Jennifer Ritchie; Jean-Sebastien Austin; Ara Schorscher-Petcu; Kara Melmed; Jan Czerminski; Rosalie A Bittong; J Brad Mokris; John K Neubert; Claudia M Campbell; Robert R Edwards; James N Campbell; Jacqueline N Crawley; William R Lariviere; Margaret R Wallace; Wendy F Sternberg; Carey D Balaban; Inna Belfer; Roger B Fillingim
Journal:  Nat Neurosci       Date:  2011-10-23       Impact factor: 24.884

10.  Antinociceptive Effects of Spinal Manipulative Therapy on Nociceptive Behavior of Adult Rats during the Formalin Test.

Authors:  Stephen M Onifer; William R Reed; Randall S Sozio; Cynthia R Long
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-26       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.